[go: up one dir, main page]

MX2018015388A - Composiciones para sistemas biologicos y metodos para preparar y utilizar las mismas. - Google Patents

Composiciones para sistemas biologicos y metodos para preparar y utilizar las mismas.

Info

Publication number
MX2018015388A
MX2018015388A MX2018015388A MX2018015388A MX2018015388A MX 2018015388 A MX2018015388 A MX 2018015388A MX 2018015388 A MX2018015388 A MX 2018015388A MX 2018015388 A MX2018015388 A MX 2018015388A MX 2018015388 A MX2018015388 A MX 2018015388A
Authority
MX
Mexico
Prior art keywords
compositions
preparing
methods
same
biological systems
Prior art date
Application number
MX2018015388A
Other languages
English (en)
Inventor
D Jones Christopher
Quintanar Nathan
Patel Roshan
Original Assignee
Smart surgical inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smart surgical inc filed Critical Smart surgical inc
Publication of MX2018015388A publication Critical patent/MX2018015388A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)

Abstract

Una composicion para influir en el crecimiento biologico incluye una solucion que tiene un primer volumen y que tiene una base fluida de pH bajo incluyendo dextrosa, y albumina, en donde la concentracion de albumina en la solucion esta entre aproximadamente 10 mg/ml y aproximadamente 150 mg/ml.
MX2018015388A 2016-06-13 2017-06-12 Composiciones para sistemas biologicos y metodos para preparar y utilizar las mismas. MX2018015388A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662349633P 2016-06-13 2016-06-13
US15/619,467 US10426796B2 (en) 2016-06-13 2017-06-10 Compositions for biological systems and methods for preparing and using the same
PCT/US2017/037055 WO2017218427A1 (en) 2016-06-13 2017-06-12 Compositions for biological systems and methods for preparing and using the same

Publications (1)

Publication Number Publication Date
MX2018015388A true MX2018015388A (es) 2019-04-29

Family

ID=60572084

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015388A MX2018015388A (es) 2016-06-13 2017-06-12 Composiciones para sistemas biologicos y metodos para preparar y utilizar las mismas.

Country Status (9)

Country Link
US (4) US10426796B2 (es)
EP (1) EP3468570A4 (es)
JP (1) JP2019521113A (es)
KR (1) KR20190018677A (es)
CN (1) CN109562130A (es)
AU (1) AU2017284186A1 (es)
CA (1) CA3026575A1 (es)
MX (1) MX2018015388A (es)
WO (1) WO2017218427A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10456423B2 (en) * 2016-06-13 2019-10-29 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
CN108823160B (zh) * 2018-07-25 2020-08-21 广州赛莱拉干细胞科技股份有限公司 一种脐带间充质干细胞原代培养基及其原代培养方法
CN109628406B (zh) * 2019-01-03 2021-02-26 北京贝来生物科技有限公司 一种治疗自身免疫疾病的间充质干细胞及其制备方法和应用
CN114452285B (zh) * 2022-02-17 2022-11-25 中国中医科学院中药研究所 一种il-17a拮抗剂在治疗糖尿病溃疡中的用途

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525519A (en) 1992-01-07 1996-06-11 Middlesex Sciences, Inc. Method for isolating biomolecules from a biological sample with linear polymers
ES2157260T3 (es) 1993-06-04 2001-08-16 Biotime Inc Solucion semejante a plasma.
US5543316A (en) 1994-04-20 1996-08-06 Diacrin, Inc. Injectable culture medium for maintaining viability of myoblast cells
JPH11322618A (ja) * 1998-05-13 1999-11-24 Asahi Medical Co Ltd 有核細胞分離回収方法及び有核細胞含有液
JP4061775B2 (ja) * 1998-05-21 2008-03-19 ニプロ株式会社 アルブミン含有腹膜透析液
US6153582A (en) 1998-11-05 2000-11-28 Bausch & Lomb Surgical, Inc. Defined serumfree medical solution for ophthalmology
US6899889B1 (en) 1998-11-06 2005-05-31 Neomend, Inc. Biocompatible material composition adaptable to diverse therapeutic indications
US7020845B1 (en) * 1999-11-15 2006-03-28 Gottfurcht Elliot A Navigating internet content on a television using a simplified interface and a remote control
US7274368B1 (en) * 2000-07-31 2007-09-25 Silicon Graphics, Inc. System method and computer program product for remote graphics processing
CN101632669B (zh) * 2000-08-04 2011-05-18 Dmi生物科学公司 二酮基哌嗪和包含它们的组合物的使用方法
EP2206772A3 (en) 2000-12-06 2010-08-04 Robert J. Hariri Method of collecting placental stem cells
DE60238801D1 (de) 2001-04-10 2011-02-10 Bioe Llc Zelltrennungszusammensetzungen und -verfahren
US20030099621A1 (en) * 2001-11-29 2003-05-29 Robert Chow Stem cell screening and transplantation therapy for HIV infection
US7771716B2 (en) * 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US20110280838A1 (en) 2007-12-27 2011-11-17 Advanced Technologies And Regenerative Medicine, Llc Treatment of intervertebral disc degeneration using human umbilical cord tissue-derived cells
AU2005221095A1 (en) 2004-03-09 2005-09-22 John J. O'neil Methods for generating insulin-producing cells
US7622108B2 (en) * 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
CA2563518C (en) 2004-04-23 2014-09-02 Bioe, Inc. Multi-lineage progenitor cells
JP2007536936A (ja) 2004-05-14 2007-12-20 ベクトン・ディキンソン・アンド・カンパニー 幹細胞集団および使用方法
US20100278725A1 (en) 2005-08-12 2010-11-04 Jiang Liu Methods and devices for lymphatic targeting
SE529040C2 (sv) * 2006-01-18 2007-04-17 Bows Pharmaceuticals Ag Förfarande för framställning av en dextranmatris för kontrollerad frisättning av insulin
WO2007121443A2 (en) 2006-04-17 2007-10-25 Bioe, Inc. Differentiation of multi-lineage progenitor cells to respiratory epithelial cells
US9598673B2 (en) * 2006-05-19 2017-03-21 Creative Medical Health Treatment of disc degenerative disease
WO2007134461A1 (en) * 2006-05-24 2007-11-29 Titan Medical Inc. Snaking robotic arm with movable shapers
EP2069479A1 (en) 2006-09-18 2009-06-17 Medizinische Universität Graz Plasma-free platelet lysate for use as a supplement in cell cultures and for the preparation of cell therapeutics
US8465733B2 (en) * 2007-11-02 2013-06-18 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition containing human mesenchymal stem cell
WO2009102959A1 (en) 2008-02-15 2009-08-20 Coalstar Industries, Inc. Apparatus and processes for production of coke and activated carbon from coal products
HU0800134D0 (en) 2008-02-26 2008-04-28 Semmelweis Egyetem Procedure for producing mineralized bone composition
CA2724839A1 (en) 2008-05-21 2009-11-26 Bioe Llc Differentiation of multi-lineage progenitor cells to pancreatic cells
WO2010132315A1 (en) * 2009-05-13 2010-11-18 Endgenitor Technologies, Inc. Enhanced hematopoietic stem cell engraftment
US9168442B2 (en) * 2009-09-21 2015-10-27 Thomas M. Covino Gaming surface and game styled after american football
MX337480B (es) 2009-09-23 2016-03-08 Davinci Biosciences Llc Celulas madre del revestimiento de cordon umbilical y metodos y material para aislar y cultivar las mismas.
EP2579882A1 (en) * 2010-06-10 2013-04-17 Aastrom Biosciences, Inc. Compositions and methods of treating no-option critical limb ischemia (cli)
US20130323712A1 (en) 2010-11-25 2013-12-05 Kaneka Corporation Method and material for separating leukocytes or mononuclear cells
US20120330438A1 (en) 2011-06-22 2012-12-27 Shaf Keshavjee Repaired organ and method for making the same
JP2015509382A (ja) * 2012-03-07 2015-03-30 チルドレンズ メディカル センター コーポレーション 組織構築体およびその使用
ES2972525T3 (es) 2012-04-24 2024-06-13 Vcell Therapeutics Inc Generación de células pluripotenciales de novo
CN104094557A (zh) * 2012-05-30 2014-10-08 株式会社东芝 铁路车辆用传送装置、铁路车辆、控制方法以及控制程序
US9283084B1 (en) 2012-07-24 2016-03-15 Thomas E. O'Hara Spinal fusion cage and vertebral body clamp
CN102920734A (zh) * 2012-11-14 2013-02-13 青岛奥克生物开发有限公司 一种间充质干细胞注射液及其制备方法和在制备治疗溃疡性结肠炎药物中的应用
WO2014099198A1 (en) * 2012-12-18 2014-06-26 Robert Chow Blood cell preparations and related methods (gen 8)
SG11201505965TA (en) 2013-01-31 2015-09-29 Ajinomoto Kk Culture method for stable undifferentiated proliferation of pluripotent stem cells
BR112015017958A2 (pt) * 2013-02-01 2017-07-11 Ampio Pharmaceuticals Inc métodos para produzir dicetopiperazinas e composições contendo dicetopiperazinas
US9241959B2 (en) 2013-03-13 2016-01-26 Mingqi TANG Kits and methods for processing stem cells from bone marrow or umbilical cord blood
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
SG11201506267XA (en) * 2013-03-15 2015-09-29 Ampio Pharmaceuticals Inc Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
JP2016509863A (ja) 2013-03-15 2016-04-04 ラーソン、マルクス カーレ、トールレイフＬＡＲＳＳＯＮ， Ｍａｒｃｕｓ Ｋａｒｅ， Ｔｏｒｌｅｉｆ 細胞、臍帯血収集のための方法及び装置、並びに細胞の単離のための方法及び装置
WO2015051088A1 (en) 2013-10-03 2015-04-09 Anthrogenesis Corporation Therapy with cells from human placenta and hematopoietic cells
US9238984B2 (en) * 2014-02-03 2016-01-19 Caterpillar, Inc. Exhaust emission prediction system and method
JP6758625B2 (ja) * 2014-10-31 2020-09-23 国立大学法人京都大学 生分解性ポリマーを用いた３次元培養方法、及び細胞移植を可能にする培養基材
WO2016076428A1 (ja) * 2014-11-14 2016-05-19 日本赤十字社 臍帯血および末梢血の凍結保存方法および凍結保存用溶液
CN107249605A (zh) * 2014-11-17 2017-10-13 阿迪塞特生物股份有限公司 工程化的γδT细胞
TWI548748B (zh) 2015-04-16 2016-09-11 台灣尖端先進生技醫藥股份有限公司 造血幹／先驅細胞之體外放大培養方法及其立即可使用之組成物
CA2989322A1 (en) 2015-06-15 2016-12-22 Vital Therapies, Inc. Composition and method for inducing anti-apoptosis, survival, or proliferation of a cell

Also Published As

Publication number Publication date
KR20190018677A (ko) 2019-02-25
US10426796B2 (en) 2019-10-01
US10363271B2 (en) 2019-07-30
US10213463B2 (en) 2019-02-26
AU2017284186A1 (en) 2019-01-03
EP3468570A1 (en) 2019-04-17
WO2017218427A1 (en) 2017-12-21
CA3026575A1 (en) 2017-12-21
JP2019521113A (ja) 2019-07-25
US20180264041A1 (en) 2018-09-20
US20170354683A1 (en) 2017-12-14
EP3468570A4 (en) 2020-01-01
US20170354684A1 (en) 2017-12-14
CN109562130A (zh) 2019-04-02
US20190328789A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
NZ743964A (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
BR112022009563A2 (pt) Compostos de pirrolotriazina atuando como inibidor de mnk
MX2017004128A (es) Derivados de diarilurea como inhibidores de quinasa p38.
PH12019501328A1 (en) 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors
AU2017261372A1 (en) Controlled release dosage form
MX2020007945A (es) Proteinas f del rsv estabilizadas y usos de las mismas.
MX2018015388A (es) Composiciones para sistemas biologicos y metodos para preparar y utilizar las mismas.
MX2018007944A (es) Composiciones inoculantes estables y metodos para producirlas.
MX387097B (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
MY204421A (en) Pyruvate kinase activators for use in treating blood disorders
MX2015013945A (es) Derivados de urea utiles como inhibidores de quinasa.
MX381625B (es) Administración y monitoreo de óxido nítrico en fluidos ex vivo.
WO2017127835A3 (en) Aqueous formulations and methods of preparation and use thereof
AU2017285758A1 (en) Method for improving salt tolerance of plant
GEP20217327B (en) Spirocycle compounds and methods of making and using same
EA201891608A1 (ru) Производные 8-амино-2-оксо-1,3-диазаспиро[4,5]декана
WO2018189661A3 (en) Methods and compounds for treating diabetes
WO2019108021A3 (ko) 토파시티닙을 포함하는 약제학적 조성물
WO2020026212A3 (en) Methods of preparing personalized blood vessels
EA201792144A1 (ru) Стабильный препарат для парентерального введения тапентадола
MX374165B (es) Aducto de ciclodextrina-panobinostat
WO2019200283A8 (en) Viscoelastic surfactant fluid composition, and method of using the same
WO2018222709A3 (en) RNA STABILIZATION USING DNA
EA033064B1 (ru) Кристаллическое соединение как ингибитор фермента семикарбазидчувствительной аминоксидазы (ssao)
PH12019502483A1 (en) Brimonidine for use and clinical trial design for geographic atrophy due to age-related macular degeneration